ALUMIS INC (ALMS) Fundamental Analysis & Valuation

NASDAQ:ALMS • US0223071020

Current stock price

23.36 USD
-1.7 (-6.78%)
At close:
23.36 USD
0 (0%)
After Hours:

This ALMS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ALMS Profitability Analysis

1.1 Basic Checks

  • In the past year ALMS has reported negative net income.
  • In the past year ALMS has reported a negative cash flow from operations.
ALMS Yearly Net Income VS EBIT VS OCF VS FCFALMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of ALMS (-50.23%) is worse than 62.69% of its industry peers.
  • ALMS has a Return On Equity (-63.71%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -50.23%
ROE -63.71%
ROIC N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALMS Yearly ROA, ROE, ROICALMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • ALMS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALMS Yearly Profit, Operating, Gross MarginsALMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ALMS Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, ALMS has more shares outstanding
  • There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALMS Yearly Shares OutstandingALMS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M 50M
ALMS Yearly Total Debt VS Total AssetsALMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 13.60 indicates that ALMS is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ALMS (13.60) is better than 87.05% of its industry peers.
  • There is no outstanding debt for ALMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 13.6
ROIC/WACCN/A
WACCN/A
ALMS Yearly LT Debt VS Equity VS FCFALMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • ALMS has a Current Ratio of 6.01. This indicates that ALMS is financially healthy and has no problem in meeting its short term obligations.
  • ALMS has a Current ratio of 6.01. This is in the better half of the industry: ALMS outperforms 70.47% of its industry peers.
  • A Quick Ratio of 6.01 indicates that ALMS has no problem at all paying its short term obligations.
  • ALMS has a better Quick ratio (6.01) than 70.98% of its industry peers.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 6.01
ALMS Yearly Current Assets VS Current LiabilitesALMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ALMS Growth Analysis

3.1 Past

  • ALMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.92%, which is quite impressive.
EPS 1Y (TTM)42.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ALMS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.63% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y66.15%
EPS Next 2Y27.85%
EPS Next 3Y19.01%
EPS Next 5Y12.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALMS Yearly Revenue VS EstimatesALMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
ALMS Yearly EPS VS EstimatesALMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. ALMS Valuation Analysis

4.1 Price/Earnings Ratio

  • ALMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ALMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALMS Price Earnings VS Forward Price EarningsALMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALMS Per share dataALMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALMS's earnings are expected to grow with 19.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.85%
EPS Next 3Y19.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ALMS Dividend Analysis

5.1 Amount

  • ALMS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ALMS Fundamentals: All Metrics, Ratios and Statistics

ALUMIS INC

NASDAQ:ALMS (3/23/2026, 8:00:01 PM)

After market: 23.36 0 (0%)

23.36

-1.7 (-6.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners43.39%
Inst Owner Change0.2%
Ins Owners0.73%
Ins Owner Change0%
Market Cap2.91B
Revenue(TTM)22.12M
Net Income(TTM)-245.15M
Analysts88
Price Target36.28 (55.31%)
Short Float %9.99%
Short Ratio2.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.49%
Min EPS beat(2)-19.57%
Max EPS beat(2)-13.42%
EPS beat(4)1
Avg EPS beat(4)7.68%
Min EPS beat(4)-20.07%
Max EPS beat(4)83.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.09%
Min Revenue beat(2)-28.51%
Max Revenue beat(2)30.69%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)87.22%
EPS NQ rev (1m)-3.36%
EPS NQ rev (3m)-3.77%
EPS NY rev (1m)-1.16%
EPS NY rev (3m)-5.94%
Revenue NQ rev (1m)-16.16%
Revenue NQ rev (3m)-16.16%
Revenue NY rev (1m)-1.4%
Revenue NY rev (3m)-3.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 131.64
P/FCF N/A
P/OCF N/A
P/B 7.57
P/tB 8.72
EV/EBITDA N/A
EPS(TTM)-4.79
EYN/A
EPS(NY)-3.23
Fwd EYN/A
FCF(TTM)-3
FCFYN/A
OCF(TTM)-2.99
OCFYN/A
SpS0.18
BVpS3.09
TBVpS2.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.23%
ROE -63.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.91%
ROA(5y)N/A
ROE(3y)-222.13%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.54%
Cap/Sales 4.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.01
Quick Ratio 6.01
Altman-Z 13.6
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)455.91%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.73%
EPS Next Y66.15%
EPS Next 2Y27.85%
EPS Next 3Y19.01%
EPS Next 5Y12.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-26.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.27%
EBIT Next 3Y-2.9%
EBIT Next 5YN/A
FCF growth 1Y-90.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.25%
OCF growth 3YN/A
OCF growth 5YN/A

ALUMIS INC / ALMS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ALUMIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ALMS.


What is the valuation status for ALMS stock?

ChartMill assigns a valuation rating of 0 / 10 to ALUMIS INC (ALMS). This can be considered as Overvalued.


What is the profitability of ALMS stock?

ALUMIS INC (ALMS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ALUMIS INC?

The Earnings per Share (EPS) of ALUMIS INC (ALMS) is expected to grow by 66.15% in the next year.